Blot S, Ruppé E, Harbarth S, Asehnoune K, Poulakou G, Luyt CE, et al. Healthcare-associated infections in adult intensive care unit patients: changes in epidemiology, diagnosis, prevention and contributions of new technologies. Intensive Crit Care Nurs. 2022;70: 103227.

Article  PubMed  PubMed Central  Google Scholar 

Tassew SG, Alebachew Woldu M, Amogne Degu W, Shibeshi W. Management of hospital-acquired infections among patients hospitalized at Zewditu memorial hospital, Addis Ababa, Ethiopia: a prospective cross-sectional study. PLoS ONE. 2020;15: e0231949.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Koulenti D, Tsigou E, Rello J. Nosocomial pneumonia in 27 ICUs in Europe: perspectives from the EU-VAP/CAP study. Eur J Clin Microbiol Infect Dis. 2017;36:1999–2006.

Article  CAS  PubMed  Google Scholar 

Ibn Saied W, Mourvillier B, Cohen Y, Ruckly S, Reignier J, Marcotte G, et al. A comparison of the mortality risk associated with ventilator-acquired bacterial pneumonia and nonventilator ICU-acquired bacterial pneumonia. Crit Care Med. 2019;47:345–52.

Article  PubMed  Google Scholar 

Vincent JL, Sakr Y, Singer M, Martin-Loeches I, Machado FR, Marshall JC, et al. Prevalence and outcomes of infection among patients in intensive care units in 2017. JAMA. 2020;323:1478–87.

Article  PubMed  PubMed Central  Google Scholar 

Metlay JP, Waterer GW, Long AC, Anzueto A, Brozek J, Crothers K, et al. Diagnosis and treatment of adults with community-acquired pneumonia. An official clinical practice guideline of the American Thoracic Society and Infectious Diseases Society of America. Am J Respir Crit Care Med. 2019;200:e45–67.

Article  PubMed  PubMed Central  Google Scholar 

Legg A, Carmichael S, Chai MG, Roberts JA, Cotta MO. Beta-lactam dose optimisation in the intensive care unit: targets, therapeutic drug monitoring and toxicity. Antibiotics (Basel). 2023;12:870.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cojutti PG, Lazzarotto D, Candoni A, Dubbini MV, Zannier ME, Fanin R, et al. Real-time TDM-based optimization of continuous-infusion meropenem for improving treatment outcome of febrile neutropenia in oncohaematological patients: results from a prospective, monocentric, interventional study. J Antimicrob Chemother. 2020;75:3029–37.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yu Z, Pang X, Wu X, Shan C, Jiang S. Clinical outcomes of prolonged infusion (extended infusion or continuous infusion) versus intermittent bolus of meropenem in severe infection: a meta-analysis. PLoS ONE. 2018;13: e0201667.

Article  PubMed  PubMed Central  Google Scholar 

Dräger S, von Rotz M, Labhardt ND, Siegemund M, Rentsch KM, Osthoff M, et al. Early target attainment with continuous infusion meropenem and piperacillin/tazobactam and utilization of therapeutic drug monitoring in critically ill patients: a retrospective cohort study from 2017 to 2020. Open Forum Infect Dis. 2023;10:ofad143.

Article  PubMed  PubMed Central  Google Scholar 

Gatti M, Cojutti PG, Pea F. Impact of attaining aggressive vs. conservative PK/PD target on the clinical efficacy of beta-lactams for the treatment of Gram-negative infections in the critically ill patients: a systematic review and meta-analysis. Crit Care. 2024;28:123.

Article  PubMed  PubMed Central  Google Scholar 

Sungurlu S, Balk RA. The role of biomarkers in the diagnosis and management of pneumonia. Infect Dis Clin North Am. 2024;38:35–49.

Article  PubMed  Google Scholar 

Póvoa P, Martin-Loeches I, Ramirez P, Bos LD, Esperatti M, Silvestre J, et al. Biomarkers kinetics in the assessment of ventilator-associated pneumonia response to antibiotics—results from the BioVAP study. J Crit Care. 2017;41:91–7.

Article  PubMed  Google Scholar 

Franceschi L, Cojutti P, Baraldo M, Pea F. Stability of generic meropenem solutions for administration by continuous infusion at normal and elevated temperatures. Ther Drug Monit. 2014;36:674–6.

Article  CAS  PubMed  Google Scholar 

Guilhaumou R, Benaboud S, Bennis Y, Dahyot-Fizelier C, Dailly E, Gandia P, et al. Optimization of the treatment with beta-lactam antibiotics in critically ill patients-guidelines from the French Society of Pharmacology and Therapeutics (Société Française de Pharmacologie et Thérapeutique-SFPT) and the French Society of Anaesthesia and Intensive Care Medicine (Société Française d’Anesthésie et Réanimation-SFAR). Crit Care. 2019;23:104.

Article  PubMed  PubMed Central  Google Scholar 

Cojutti PG, Gatti M, Rinaldi M, Tonetti T, Laici C, Mega C, et al. Impact of maximizing Css/MIC ratio on efficacy of continuous infusion meropenem against documented gram-negative infections in critically ill patients and population pharmacokinetic/pharmacodynamic analysis to support treatment optimization. Front Pharmacol. 2021;12: 781892.

Article  PubMed  PubMed Central  Google Scholar 

Dhaese S, Van Vooren S, Boelens J, De Waele J. Therapeutic drug monitoring of β-lactam antibiotics in the ICU. Expert Rev Anti Infect Ther. 2020;18:1155–64.

Article  CAS  PubMed  Google Scholar 

Ramirez S, Scapaticci M, Barbella F, Panico MM, Fecca IA, Cocchini B, et al. Development of a rapid LC-MS/MS method for simultaneous quantification of ten commonly used antibiotic drugs in human serum. J Pharm Biomed Anal. 2024;244: 116119.

Article  CAS  PubMed  Google Scholar 

Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF, Feldman HI, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150:604–12.

Article  PubMed  PubMed Central  Google Scholar 

Koiwai K, El-Cheikh R, Thai HT, Brillac C, Fau JB, Veyrat-Follet C, et al. PK/PD modeling analysis for dosing regimen selection of isatuximab as single agent and in combination therapy in patients with multiple myeloma. CPT Pharmacometr Syst Pharmacol. 2021;10:928–40.

Article  CAS  Google Scholar 

Rawson TM, Charani E, Moore LSP, Gilchrist M, Georgiou P, Hope W, et al. Exploring the use of c-reactive protein to estimate the pharmacodynamics of vancomycin. Ther Drug Monit. 2018;40:315–21.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Märtson AG, Sturkenboom MGG, Knoester M, van der Werf TS, Alffenaar JC, Hope W, et al. Standard ganciclovir dosing results in slow decline of cytomegalovirus viral loads. J Antimicrob Chemother. 2022;77:466–73.

Article  PubMed  Google Scholar 

Cojutti PG, Heffernan AJ, Tängdén T, Della Siega P, Tascini C, Roberts JA, et al. Population pharmacokinetic and pharmacodynamic analysis of valganciclovir for optimizing preemptive therapy of cytomegalovirus infections in kidney transplant recipients. Antimicrob Agents Chemother. 2023;67: e0166522.

Article  PubMed  Google Scholar 

Sanz Codina M, Gatti M, Troisi C, Fornaro G, Pasquini Z, Trapani F, et al. Relationship between pharmacokinetic/pharmacodynamic target attainment and microbiological outcome in critically ill COVID-19 patients with documented gram-negative superinfections treated with TDM-guided continuous-infusion meropenem. Pharmaceutics. 2022;14:1585.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mattioli F, Fucile C, Del Bono V, Marini V, Parisini A, Molin A, et al. Population pharmacokinetics and probability of target attainment of meropenem in critically ill patients. Eur J Clin Pharmacol. 2016;72:839–48.

Article  CAS  PubMed  Google Scholar 

Jaruratanasirikul S, Thengyai S, Wongpoowarak W, Wattanavijitkul T, Tangkitwanitjaroen K, Sukarnjanaset W, et al. Population pharmacokinetics and Monte Carlo dosing simulations of meropenem during the early phase of severe sepsis and septic shock in critically ill patients in intensive care units. Antimicrob Agents Chemother. 2015;59:2995–3001.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ulldemolins M, Soy D, Llaurado-Serra M, Vaquer S, Castro P, Rodríguez AH, et al. Meropenem population pharmacokinetics in critically ill patients with septic shock and continuous renal replacement therapy: influence of residual diuresis on dose requirements. Antimicrob Agents Chemother. 2015;59:5520–8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Roberts JA, Kirkpatrick CM, Roberts MS, Robertson TA, Dalley AJ, Lipman J. Meropenem dosing in critically ill patients with sepsis and without renal dysfunction: intermittent bolus versus continuous administration? Monte Carlo dosing simulations and subcutaneous tissue distribution. J Antimicrob Chemother. 2009;64:142–50.

Article  CAS  PubMed  Google Scholar 

Niib